Environmentally classified pharmaceuticals

Two substances may have the same risk values but different PBT values, but the risk assessment can also be different even if the PBT values are the same. When assessing a medication's environmental impact, consideration should be given to both environmental risk and environmental hazard since bioaccumulation and persistence are not included in the risk assessment.

The Swedish Association of the Pharmaceutical Industry conducted the environmental risk assessment, beginning in 2005.

How to read the table

Last updated: 2011-08-19

« New search


H Systemic hormonal preparations, excl sex hormones and insulins

 Substance  Risk  PBT  P  B  T  Volume in DDD
H01 Pituitary and hypothalamic hormones and anlogues
ganirelix exempt         11 757 
nafarelin exempt         153 585 
oxytocin exempt         49 649 
cetrorelix exempt         754 
carbetocin exempt        
lanreotide exempt         18 050 
pegvisomant exempt         1 560 
somatropin exempt         291 325 
terlipressin exempt         418 
H02 Corticosteroids for systemic use
hydrocortisone cannot be excl 1
N.B.
0 0 1
N.B.
429 014 
C, E 9 858 435 
triamcinolone cannot be excl 4
N.B.
3 0 1
N.B.
181 568 
E 2 709 040 
betamethasone cannot be excl 9
N.B.
3 3 3
N.B.
2 298 149 
E 7 609 925 
fludrocortisone cannot be excl 211 200 
methylprednisolone cannot be excl 324 274 
prednisolone cannot be excl 4 732 223 
dexamethasone cannot be excl 37 397 
H03 Thyroid therapy
levothyroxine cannot be excl 17 762 255 
liothyronine cannot be excl 72 859 
H05 Calcium homeostasis
teriparatide exempt         10 688 
parathyroid hormone exempt         2 716